	Palliative Management of Inoperable Vesicovaginal Fistula in Cervical Cancer Patient Using Bilateral Single-J Stents and Bladder Stoma: A Pilot Study. Int Urogynecol J Shi Y, Sherryn S, Wang S, Lei Z, Yang L, Gao Q, Zheng Q, Zhang B. PMID: 42726218 [PubMed - as supplied by publisher]
	Â¹â·â·Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer With Complex Renal Conditions: A Case Series. Clin Nucl Med Usmani S, Al Balushi A, Al Saadi S, Jain A, Al Harthy M, Ismaila A, Al Busaidi A, Al Riyami K. PMID: 42725474 [PubMed - as supplied by publisher]
	Treatment Patterns and Long-Term Survival Outcomes in Muscle-Invasive Bladder Cancer: A Decade-Long Single-Institution Retrospective Cohort Study. J Cancer Allied Spec Ranjha FR, Rashid A, Adnan A, Kashif M, Tanveer I, Sadaf T, Hashmi ZH, Munawar A. PMID: 42725309 [PubMed]
	Associations between a mixture of trace elements and bladder cancer occurrence: A study of possible reverse causation. Environ Epidemiol Kamenetsky ME, Koutros S, Spaur M, Kim SD, Karagas MR, Johnson A, Baris D, Le XC, Silverman DT, Keil AP. PMID: 42725121 [PubMed]
	Ipsilateral recurrences after kidney-sparing surgery for upper tract urothelial carcinoma: a systematic review and meta-analysis. BMJ Oncol Ståhl E, Saha S, Bobjer J, Hagberg O, Liedberg F. PMID: 42724747 [PubMed]
	Predictive value of baseline risk factors and early prostate-specific antigen (PSA) kinetics for achieving deep PSA decline in metastatic hormone-sensitive prostate cancer: implications for treatment intensification. Transl Cancer Res Zhou P, Han Z, Wang Y, Yang R, Yu W. PMID: 42724687 [PubMed]
	Incremental value of prostate-specific antigen density beyond PI-RADS and conventional MRI features for predicting the highest ISUP grade group in patients with prostate cancer diagnosed at initial systematic prostate biopsy. Am J Cancer Res Fan D, Niu R, Zhou F, Yang L, Zhang C. PMID: 42724578 [PubMed]
	Burden of Treatment-Induced Vasomotor Symptoms in Men With Prostate Cancer on Androgen-Deprivation Therapy: A Systematic Literature Review. Prostate Cancer Ajmera M, Lou KJ, Ng S, Helbing M. PMID: 42724429 [PubMed]
	A seven-variable clinical prediction model for bone metastasis at initial diagnosis of prostate cancer. Am J Cancer Res Ni Y, Tao N, An H. PMID: 42724338 [PubMed]
	Clinical and MRI features for predicting maximum cancer involvement of >50% in a single biopsy core among patients diagnosed with prostate cancer at initial systematic biopsy: a machine learning study. Am J Cancer Res Fan D, Li J, Niu R, Zhou F, Hu J, Yang L. PMID: 42724262 [PubMed]
	Association of AI-derived abdominal organ volumetry with postoperative outcomes in clear cell renal cell carcinoma: a multicentre study. Ann Med Lou J, Ren Y, Gong B, Guo Y, Lv D, Shan S, Lu Q, Sun A, Wu J, Chen Y, Yao X, Yang L. PMID: 42723375 [PubMed - indexed for MEDLINE]
	Bulk and single-cell transcriptome-based integrative analysis of an rRNA processing-related prognostic signature with functional validation of DDX47 in clear cell renal cell carcinoma. BMC Cancer Liu J, Tan H, Yang J, Zhong J, Zhou Q, Guo J. PMID: 42723025 [PubMed - indexed for MEDLINE]
	Prognosis Comparison Between Synchronous and Metachronous Metastasis of Renal Cell Carcinoma: A Meta-Analysis and Systematic Review. Ann Surg Oncol Geng C, Ji X, Liu T. PMID: 42722945 [PubMed - as supplied by publisher]
	Response to comment on: cardiovascular and prostate cancer risk associated with testosterone replacement therapy-a systematic review and meta-analysis of 41 randomized controlled trials. Int J Impot Res Garcia-Becerra CA, Arias-Gallardo MI, Juarez-Garcia JE, Eskenazi F, Dugarte JP, Martinez Holst MA, Soltero-Molinar V, Garcia-Becerra N, Garcia-Gutierrez CM. PMID: 42722801 [PubMed - as supplied by publisher]
	Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival. Urol Oncol Wang J. PMID: 42722558 [PubMed - as supplied by publisher]
	Diagnostic Performance of [(68)Ga]Ga-DPI-4452 PET/CT in Patients with Clear Cell Renal Cell Carcinoma: A Prospective Trial. J Nucl Med Wang D, Du L, Wang Y, Song J, Zhang X, Xu X, Sun H, Fan J, Ma X, Gu L, Wang R. PMID: 42722441 [PubMed - as supplied by publisher]
	Exploring the impact of syndecans in prostate cancer: Stage-specific roles and therapeutic implications. Eur J Cell Biol Machado RS, Tamura RE, Götte M, Onyeisi JOS. PMID: 42721521 [PubMed - as supplied by publisher]
	Total periurethral anatomical preservation during single-port extraperitoneal robot-assisted radical prostatectomy using a modified hood technique. J Robot Surg Lee CU, Choi YH. PMID: 42720880 [PubMed - indexed for MEDLINE]
	CRISPR-Cas9â€‘based lipid nanocarriers for advanced therapy of urinary bladder cancer. Nanomedicine (Lond) Mukherjee S, Karati D, Sarkar S, Ash D, Ganguly SC, Dutta A, Kesarla R. PMID: 42720610 [PubMed - as supplied by publisher]
	A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma. Future Oncol Hatoum F, Dyer B, Heiligh J, Poehlman T, Zhang J, Jameel G, Mizelle S, Patel A, Schneider A, Fazili A, Johnson JS, Miller JW, Roman Souza G, Mahmoud N, Gullapalli K, Kim Y, Spiess PE, Gatenby R, Anderson ARA, Chahoud J. PMID: 42719952 [PubMed - as supplied by publisher]

Articles 1 - 20 / 181365

Page 1 of 9069



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy